MedPath

Post Marketing Observational Study to Assess the Effectiveness and Safety of Prochlorperazine In Patients with Acute Vertigo

Phase 4
Completed
Conditions
Health Condition 1: G939- Disorder of brain, unspecified
Registration Number
CTRI/2022/01/039287
Lead Sponsor
Abbott Healthcare Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients of either sex in the age group of 18-65 years.

2. Patients diagnosed with Meniere’s disease, vestibular neuritis, labyrinthitis, or

post-operative vertigo.

3. Patients willing to participate in the study and sign an informed consent form

Exclusion Criteria

1. Patients diagnosed with BPPV.

2. Patients with history of psychiatric illness.

3. Patients on anti-psychotic or anti-depressant medication.

4. Patients with history of cardiovascular, kidney or liver disorder.

5. Patients requiring hospitalization for any cause.

6. Patients with suspected or established subcortical brain damage, with or without

hypothalamic damage.

7. Pregnant and nursing women.

8. Women with childbearing potential who are not practicing a reliable method of birth

control.

9. Patients with a known history of hypersensitivity to phenothiazine derivatives

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath